Zosuquidar (LY335979) 3HCl: Selective P-gp Inhibitor for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a highly selective modulator of the P-glycoprotein (P-gp) efflux pump, enabling the reversal of chemotherapy resistance in various cancer cell models (https://doi.org/10.1016/j.biopha.2025.118665). At low micromolar concentrations, Zosuquidar restores sensitivity to agents such as vinblastine and doxorubicin in P-gp overexpressing cells. Preclinical in vivo studies show enhanced antitumor efficacy and prolonged survival in models of resistant leukemia and non-small cell lung carcinoma, with minimal effect on chemotherapeutic pharmacokinetics. Clinical phase I/II data report effective P-gp inhibition and low toxicity when Zosuquidar is combined with standard regimens. APExBIO supplies Zosuquidar (LY335979) 3HCl (SKU A3956) in a ready-to-use, research-grade format (product link).

Biological Rationale

P-glycoprotein (P-gp; ABCB1) is an ATP-dependent transmembrane efflux pump. It is widely expressed in brain, liver, intestine, kidney, and many tumors. P-gp actively transports structurally diverse substrates—including chemotherapeutic agents—out of cells, contributing to multidrug resistance (MDR) in cancer (Sun et al., 2025, DOI). Overexpression of P-gp in tumor cells reduces intracellular drug accumulation, resulting in decreased efficacy of agents such as vinblastine, doxorubicin, etoposide, and paclitaxel. Inhibition of P-gp function is a validated strategy for reversing MDR and improving chemotherapy outcomes (internal link; this article provides updated mechanistic precision and clinical context not covered in previous summaries).

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar is a tricyclic piperazine derivative with high affinity and selectivity for P-gp. It acts as a competitive inhibitor, binding to the drug-substrate site and blocking the efflux of chemotherapeutic agents (SKU A3956, APExBIO). Zosuquidar does not significantly inhibit other ATP-binding cassette (ABC) transporters at recommended concentrations. Structural studies show that Zosuquidar's binding prevents ATP hydrolysis cycles necessary for the P-gp transport function (Sun et al., 2025, DOI). This restoration of intracellular chemotherapeutic concentration underlies its MDR reversal effect. For more comprehensive mechanistic analysis, see this linked article, while the current review adds new clinical evidence and updated workflow parameters.

Evidence & Benchmarks

• Zosuquidar (LY335979) 3HCl at 0.1–1 μM restores vinblastine and doxorubicin cytotoxicity in P-gp overexpressing leukemia and tumor cell lines in vitro (Sun et al., 2025, DOI).
• In murine models, co-administration of Zosuquidar enhances the antitumor effects of paclitaxel and prolongs survival in multidrug resistant leukemia xenografts (Sun et al., 2025, DOI).
• Pharmacokinetic profiling shows Zosuquidar does not significantly alter plasma half-life, AUC, or clearance of partner chemotherapeutics (Sun et al., 2025, Table 3, DOI).
• Phase I/II trials in non-Hodgkin's lymphoma and advanced solid tumors demonstrate effective P-gp inhibition, with minimal added toxicity when Zosuquidar is used alongside CHOP or vinorelbine regimens (Sun et al., 2025, DOI).
• Multiple dosing in vivo further increases cytotoxic drug retention in P-gp positive tissues without significant adverse effects (Sun et al., 2025, Figure 2, DOI).

For actionable protocols and troubleshooting, see this scenario-driven guide, which this article extends by summarizing clinical and mechanistic advances since initial publication.

Applications, Limits & Misconceptions

Zosuquidar is most effective in experimental and translational models of multidrug resistance (MDR), particularly where P-gp overexpression has been confirmed. It is validated for use in both in vitro cytotoxicity assays and in vivo xenograft models. Clinical studies focus on combination regimens in hematologic malignancies and solid tumors. Zosuquidar is soluble in DMSO and stable at -20°C; long-term storage of solutions is not recommended due to possible degradation (SKU A3956, APExBIO).

Common Pitfalls or Misconceptions

• Zosuquidar does not inhibit all ABC transporters—selectivity is highest for P-gp (ABCB1), with minimal effect on MRP1 or BCRP at standard concentrations.
• It is ineffective in MDR models where resistance is mediated by non-P-gp mechanisms (e.g., altered apoptosis, non-ABC efflux pumps).
• Zosuquidar does not enhance drug activity in cells lacking P-gp overexpression.
• Long-term storage of diluted solutions at room temperature can result in compound degradation and loss of activity.
• Pharmacokinetic interactions with CYP450s are negligible at recommended doses, but off-target effects at higher concentrations are possible and should be controlled experimentally.

Workflow Integration & Parameters

Experimental protocols typically add Zosuquidar at 0.1–1 μM to culture medium for in vitro reversal assays. For in vivo studies, dosing regimens range from 5 to 20 mg/kg, administered in combination with chemotherapeutic agents. Zosuquidar is compatible with viability, apoptosis, and cytotoxicity assays. It is recommended to use freshly prepared DMSO solutions and to store aliquots at -20°C. For reproducible MDR reversal, confirm P-gp expression in model systems before use. Researchers should reference the A3956 product page (link) for detailed solubility, storage, and handling guidelines. For expanded protocols and troubleshooting, this article updates and contextualizes guidance originally presented in scenario-driven best practices.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a validated, selective P-gp inhibitor for reversing multidrug resistance in cancer research. Its efficacy and safety are supported by preclinical and phase I/II clinical benchmarks. APExBIO's research-grade formulation (SKU A3956) enables reproducible studies of P-gp-mediated MDR. Future work will refine its integration with next-generation chemotherapy and personalized oncology regimens (Sun et al., 2025).